SP
SIH Partners Portfolio holdings
AUM
$1.05B
1-Year Est. Return
21.73%
1 Year Est. Return
+21.73%
AUM
$1.05B
AUM Growth
-$86.2M
(-7.6%)
Holding
292
Top Buys
| 1 | +$122M | |
| 2 | +$60.2M | |
| 3 | +$49.7M | |
| 4 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$46M |
| 5 |
Li Auto
LI
|
+$25.7M |
Top Sells
| 1 | +$136M | |
| 2 | +$125M | |
| 3 | +$56.7M | |
| 4 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$28.1M |
| 5 |
KraneShares CSI China Internet ETF
KWEB
|
+$25.8M |
Sector Composition
| 1 | Consumer Discretionary | 52.11% |
| 2 | Materials | 9.59% |
| 3 | Communication Services | 8.3% |
| 4 | Technology | 4.16% |
| 5 | Healthcare | 3.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Pfizer
PFE
$141B
| – | – |
-108,165
|
|
||
277
Precigen
PGEN
$1.38B
| – | – |
-19,203
|
|
||
278
Personalis
PSNL
$792M
| – | – |
-19,966
|
|
||
279
PTC Therapeutics
PTCT
$5.28B
| – | – |
-4,962
|
|
||
280
Qfin Holdings
QFIN
$3.47B
| – | – |
-53,800
|
|
||
281
Quantum-Si Incorporated
QSI
$445M
| – | – |
-10,624
|
|
||
282
Ultragenyx Pharmaceutical
RARE
$3.19B
| – | – |
-5,738
|
|
||
283
Regeneron Pharmaceuticals
REGN
$62B
| – | – |
-7,750
|
|
||
284
Avidity Biosciences
RNA
$6.84B
| – | – |
-7,533
|
|
||
285
Roivant Sciences
ROIV
$12.3B
| – | – |
-44,403
|
|
||
286
Royalty Pharma
RPRX
$15.9B
| – | – |
-26,881
|
|
||
287
Revolution Medicines
RVMD
$9.9B
| – | – |
-11,702
|
|
||
288
Recursion Pharmaceuticals
RXRX
$2.51B
| – | – |
-51,202
|
|
||
289
Rhythm Pharmaceuticals
RYTM
$7.25B
| – | – |
-3,980
|
|
||
290
Sana Biotechnology
SANA
$1.41B
| – | – |
-13,427
|
|
||
291
Summit Therapeutics
SMMT
$14.3B
| – | – |
-46,492
|
|
||
292
Sarepta Therapeutics
SRPT
$2.35B
| – | – |
-5,867
|
|